Evista contains the active ingredient raloxifene hydrochloride. It is formulated as a tablet<\/a> for oral administration. Each tablet is white, elliptical, and imprinted with the manufacturer’s mark and a code. The medication is available in 60 mg strength.<\/p>\n Evista is classified as a selective estrogen<\/a> receptor modulator (SERM). It exhibits estrogen-agonistic effects on bones and lipid<\/a> metabolism while having estrogen-antagonistic effects on uterine<\/a> and breast tissues. This dual action helps in maintaining bone density and reducing the risk of vertebral fractures.<\/p>\n Evista is primarily indicated for the treatment and prevention of osteoporosis in postmenopausal<\/a> women. Additionally, it is indicated to reduce the risk of invasive breast cancer<\/a> in postmenopausal women with osteoporosis or those at high risk for invasive breast cancer.<\/p>\n Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes across various tissues. It reduces bone resorption and turnover, leading to an increase in bone mineral density. The medication also modifies lipid profiles by decreasing total and LDL cholesterol<\/a> levels.<\/p>\n After oral administration, raloxifene is rapidly absorbed. The drug undergoes extensive first-pass metabolism, with an absolute bioavailability of approximately 2%. It exhibits a half-life of approximately 27.7 hours due to enterohepatic recycling. Raloxifene is highly bound to plasma proteins, primarily albumin.<\/p>\n Evista exerts its effects predominantly through selective modulation of estrogen receptors. By acting as an estrogen agonist on bone and lipids, it helps maintain bone mass and reduces the risk of vertebral fractures. Its antagonistic effects on uterine and breast tissue decrease estrogen stimulation<\/a>, reducing the risk of cancer in estrogen-sensitive tissues.<\/p>\n Evista is prescribed as one 60 mg tablet taken once daily by mouth. It can be administered with or without food. Consistency in timing of dosage each day ensures optimal therapeutic outcomes and assists in establishing a routine for the patient.<\/p>\n Store Evista tablets at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). The medication should be kept in a tightly closed container away from moisture and heat. Protect the tablets from light by keeping them in their original packaging.<\/p>\n Evista may interact with various drugs affecting its metabolism. Concurrent use with cholestyramine significantly reduces raloxifene absorption. Caution should be exercised when combining with highly protein-bound drugs, as displacement interactions may occur. Raloxifene may also alter the effects of warfarin, requiring monitoring of INR levels.<\/p>\n Evista is contraindicated in patients with active or past deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis. It should not be used in women who are or may become pregnant. Not suitable for individuals with a known hypersensitivity to raloxifene.<\/p>\nPharmacological Classification<\/h2>\n
Indications for Use<\/h2>\n
Pharmacodynamics Details<\/h2>\n
Pharmacokinetics Properties<\/h2>\n
Mechanism of Action<\/h2>\n
Dosing and Administration<\/h2>\n
Storage Recommendations<\/h2>\n
Drug Interactions Overview<\/h2>\n
Contraindications Specification<\/h2>\n
Adverse Effects Potential<\/h2>\n